论文部分内容阅读
目的:探讨血清HE4、CA125以及CA19-9的水平变化和妇科卵巢肿瘤的关系,为临床卵巢肿瘤的诊断和预后判断提供资料依据。方法:通过电化学发光法分别检测云南省某医院妇科卵巢癌患者、良性卵巢肿瘤患者和健康女性血清HE4、CA125以及CA19-9的阳性率差异,统计比较血清HE4、CA125以及CA19-9与卵巢肿瘤的关联意义。结果:卵巢癌组HE4、CA125以及CA19-9阳性率分别为68.57%、88.57%以及31.42%,良性卵巢肿瘤组HE4、CA125、CA19-9的阳性率分别为0.00%、17.78%和11.11%,健康人群对照组均为0.00%。卵巢癌患者的血清HE4、CA125以及CA19-9的检测水平显著高于良性卵巢肿瘤组和对照组(P<0.05)。结论:血清HE4、CA125以及CA19-9水平的升高与女性卵巢肿瘤的发生有显著关联,特别是对于卵巢癌的患者多数都可检测一项或者多项指标的显著变化,3项指标的联合检测对于卵巢肿瘤尤其是恶性肿瘤的早期发现以及辅助诊断具有重要的临床价值,值得推广使用。
Objective: To investigate the relationship between serum levels of HE4, CA125 and CA19-9 and gynecological ovarian tumors, and provide evidences for the diagnosis and prognosis of clinical ovarian tumors. Methods: The positive rates of HE4, CA125 and CA19-9 in serum of gynecological ovarian cancer patients, benign ovarian tumor patients and healthy women in a hospital of Yunnan Province were detected respectively by electrochemiluminescence method. The levels of serum HE4, CA125 and CA19-9 were compared with ovarian Tumor correlations. Results: The positive rates of HE4, CA125 and CA19-9 in ovarian cancer group were 68.57%, 88.57% and 31.42% respectively. The positive rates of HE4, CA125 and CA19-9 in ovarian cancer group were 0.00%, 17.78% and 11.11% Healthy control group were 0.00%. The levels of serum HE4, CA125 and CA19-9 in patients with ovarian cancer were significantly higher than those in benign ovarian tumor group and control group (P <0.05). Conclusion: The elevated serum levels of HE4, CA125 and CA19-9 are significantly associated with the occurrence of ovarian tumors in women, especially for the majority of patients with ovarian cancer can detect significant changes in one or more of the indicators, the combination of three indicators Detection of ovarian tumors, especially malignant tumors, especially the early detection and diagnosis of important clinical value, it is worth promoting the use of.